跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 1,444 条关于
“Complement C3 Glomerulopathy”
全部
1,444
临床试验
380
药物
70
机构
2
资讯
992
去年
Zaltenibart Receives FDA Rare Pediatric Disease Designation for C3 Glomerulopathy
去年
Ruxoprubart Receives FDA IND Clearance for Phase II Trials in IgAN and Dermatomyositis
7个月前
Novartis Reports Positive Phase III Results for Fabhalta in Rare Kidney Disease C3 Glomerulopathy
去年
Novartis' Fabhalta Demonstrates Sustained Benefits in Phase III Trial for C3 Glomerulopathy
去年
Eleva Partners with 3PBIOVIAN to Scale Production of Novel Complement Modulator for Rare Diseases
去年
Novartis' Fabhalta Shows Sustained Efficacy in C3 Glomerulopathy at 12 Months
去年
Fabhalta Demonstrates Sustained Efficacy in C3 Glomerulopathy Patients at 12 Months
去年
Error parsing response
去年
Pegcetacoplan Shows Promise in C3 Glomerulopathy and IC-MPGN: VALIANT Trial Results
去年
Eleva Advances Factor H Therapy CPV-104 into First-in-Human Trial for Rare Kidney Disease C3 Glomerulopathy
第 1 页，共 100 页
上一页
下一页
